We can't find the internet
Attempting to reconnect
13750.1;12 PFFLE-LS
Antibody-based therapy for type-2 diabetes
Résumé
Antibody-based therapy for type-2 diabetes
Textes supplémentaires
Abstract
The project focuses on the development of an immunotherapy targeting toxic aggregates of islet amyloid polypeptide which are associated with the loss of pancreatic beta-cells in type-2 diabetes patients. Combining Neurimmune¿s expertise in the discovery and validation of human antibodies and academic partners' know-how in diabetes and amyloidosis research, the joint program is aimed at providing in vivo proof-ofconcept for this novel therapeutic strategy for type-2 diabetes.
Participants
Roger Nitsch
Kontaktperson
nitsch@bli.uzh.ch
Universität Zürich Roger Nitsch August-Forel-Strasse 1 Abteilung f. Psychiatrische Forschu 8008 Zürich ZH CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2012-02-29
- Date de fin
- 2015-11-10
- Coûts totaux approuvés
- CHF 900000.00
- Section
- 5 KTI
- Domaine politique NABS
- Nicht aufteilbare / nicht zuteilbare Forschung
Disciplines de recherche
- T490 Biotechnology 100.0%